Coprescription of Chinese herbal medicine and Western medication among female patients with breast cancer in Taiwan: analysis of national insurance claims

Bih-Ru Wang,1,2,* Yuh-Lih Chang,1,2,* Tzeng-Ji Chen,3,4 Jen-Hwey Chiu,5,6 Jing Chong Wu,7 Min-Shan Wu,1 Chia-Lin Chou,1 Yueh-Ching Chou1,2,81Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan; 2Department and Institute of Pharmacology, National Yang-Ming University, Taipei, Tai...

Full description

Bibliographic Details
Main Authors: Wang BR, Chang YL, Chen TJ, Chiu JH, Wu JC, Wu MS, Chou CL, Chou YC
Format: Article
Language:English
Published: Dove Medical Press 2014-05-01
Series:Patient Preference and Adherence
Online Access:http://www.dovepress.com/coprescription-of-chinese-herbal-medicine-and-western-medication-among-a16711
_version_ 1811281530070237184
author Wang BR
Chang YL
Chen TJ
Chiu JH
Wu JC
Wu MS
Chou CL
Chou YC
author_facet Wang BR
Chang YL
Chen TJ
Chiu JH
Wu JC
Wu MS
Chou CL
Chou YC
author_sort Wang BR
collection DOAJ
description Bih-Ru Wang,1,2,* Yuh-Lih Chang,1,2,* Tzeng-Ji Chen,3,4 Jen-Hwey Chiu,5,6 Jing Chong Wu,7 Min-Shan Wu,1 Chia-Lin Chou,1 Yueh-Ching Chou1,2,81Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan; 2Department and Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan; 3Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; 4Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan; 5Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan; 6Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; 7Traditional Medicine Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 8College of Pharmacy, Taipei Medical University, Taipei, Taiwan*These authors contributed equally to this workBackground: Many female breast cancer (FBC) patients take Chinese herbal medicine (CHM) and Western medication (WM) concurrently in Taiwan. Despite the possibility of interactions between the CHM and WM mentioned in previous studies, the pattern of these coprescriptions in FBC patients remains unclear. Hence, the aim of the present study is to investigate the utilization of coprescriptions of CHM and WM among the FBC patients in Taiwan.Methods: The study was a cross-sectional survey using the sampled cohort in 2009 obtained from the National Health Insurance Research Database in Taiwan. There were 3,507 FBC patients identified from the registry for catastrophic illness patients. Ambulatory visit records, corresponding prescriptions, and the data of beneficiaries belonging to the FBC patients were further extracted. A total of 1,086 FBC patients used CHM at least once. CHM and WM prescribed within any overlapping duration were defined as coprescriptions.Results: There were 868 (80.0%) patients simultaneously receiving CHM and WM. A total of 4,927 CHM prescriptions and 6,358 WM prescriptions were prescribed concurrently. Among these coprescriptions, the most frequently used CHM was jia-wei-xiao-yao-san (21.2%), and the most frequently coprescribed WM was acetaminophen (38.9%), followed by tamoxifen (25.5%). There were 346 patients using systemic adjuvant therapy and CHM concurrently. The most commonly coprescribed CHM with chemotherapy, endocrine therapy, and trastuzumab was xiang-sha-liu-jun-zi-tang, jia-wei-xiao-yao-san, and zhi-gan-cao-tang, respectively.Conclusion: The combined use of CHM with WM is prevalent. The main purpose of combining CHM with systemic cancer treatment is to alleviate the treatment-related adverse effects. However, the combination may result in the potential risk of drug–herb interactions. Further clinical studies are needed to evaluate the efficacy and safety of the CHM and WM coprescriptions for FBC patients.Keywords: drug utilization patterns, complementary and alternative medicine, pharmacoep-idemiology
first_indexed 2024-04-13T01:35:17Z
format Article
id doaj.art-63932a22c49643e0835538b2fdf9529d
institution Directory Open Access Journal
issn 1177-889X
language English
last_indexed 2024-04-13T01:35:17Z
publishDate 2014-05-01
publisher Dove Medical Press
record_format Article
series Patient Preference and Adherence
spelling doaj.art-63932a22c49643e0835538b2fdf9529d2022-12-22T03:08:24ZengDove Medical PressPatient Preference and Adherence1177-889X2014-05-012014default67168216711Coprescription of Chinese herbal medicine and Western medication among female patients with breast cancer in Taiwan: analysis of national insurance claimsWang BRChang YLChen TJChiu JHWu JCWu MSChou CLChou YCBih-Ru Wang,1,2,* Yuh-Lih Chang,1,2,* Tzeng-Ji Chen,3,4 Jen-Hwey Chiu,5,6 Jing Chong Wu,7 Min-Shan Wu,1 Chia-Lin Chou,1 Yueh-Ching Chou1,2,81Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan; 2Department and Institute of Pharmacology, National Yang-Ming University, Taipei, Taiwan; 3Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; 4Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan; 5Division of General Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan; 6Institute of Traditional Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan; 7Traditional Medicine Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan; 8College of Pharmacy, Taipei Medical University, Taipei, Taiwan*These authors contributed equally to this workBackground: Many female breast cancer (FBC) patients take Chinese herbal medicine (CHM) and Western medication (WM) concurrently in Taiwan. Despite the possibility of interactions between the CHM and WM mentioned in previous studies, the pattern of these coprescriptions in FBC patients remains unclear. Hence, the aim of the present study is to investigate the utilization of coprescriptions of CHM and WM among the FBC patients in Taiwan.Methods: The study was a cross-sectional survey using the sampled cohort in 2009 obtained from the National Health Insurance Research Database in Taiwan. There were 3,507 FBC patients identified from the registry for catastrophic illness patients. Ambulatory visit records, corresponding prescriptions, and the data of beneficiaries belonging to the FBC patients were further extracted. A total of 1,086 FBC patients used CHM at least once. CHM and WM prescribed within any overlapping duration were defined as coprescriptions.Results: There were 868 (80.0%) patients simultaneously receiving CHM and WM. A total of 4,927 CHM prescriptions and 6,358 WM prescriptions were prescribed concurrently. Among these coprescriptions, the most frequently used CHM was jia-wei-xiao-yao-san (21.2%), and the most frequently coprescribed WM was acetaminophen (38.9%), followed by tamoxifen (25.5%). There were 346 patients using systemic adjuvant therapy and CHM concurrently. The most commonly coprescribed CHM with chemotherapy, endocrine therapy, and trastuzumab was xiang-sha-liu-jun-zi-tang, jia-wei-xiao-yao-san, and zhi-gan-cao-tang, respectively.Conclusion: The combined use of CHM with WM is prevalent. The main purpose of combining CHM with systemic cancer treatment is to alleviate the treatment-related adverse effects. However, the combination may result in the potential risk of drug–herb interactions. Further clinical studies are needed to evaluate the efficacy and safety of the CHM and WM coprescriptions for FBC patients.Keywords: drug utilization patterns, complementary and alternative medicine, pharmacoep-idemiologyhttp://www.dovepress.com/coprescription-of-chinese-herbal-medicine-and-western-medication-among-a16711
spellingShingle Wang BR
Chang YL
Chen TJ
Chiu JH
Wu JC
Wu MS
Chou CL
Chou YC
Coprescription of Chinese herbal medicine and Western medication among female patients with breast cancer in Taiwan: analysis of national insurance claims
Patient Preference and Adherence
title Coprescription of Chinese herbal medicine and Western medication among female patients with breast cancer in Taiwan: analysis of national insurance claims
title_full Coprescription of Chinese herbal medicine and Western medication among female patients with breast cancer in Taiwan: analysis of national insurance claims
title_fullStr Coprescription of Chinese herbal medicine and Western medication among female patients with breast cancer in Taiwan: analysis of national insurance claims
title_full_unstemmed Coprescription of Chinese herbal medicine and Western medication among female patients with breast cancer in Taiwan: analysis of national insurance claims
title_short Coprescription of Chinese herbal medicine and Western medication among female patients with breast cancer in Taiwan: analysis of national insurance claims
title_sort coprescription of chinese herbal medicine and western medication among female patients with breast cancer in taiwan analysis of national insurance claims
url http://www.dovepress.com/coprescription-of-chinese-herbal-medicine-and-western-medication-among-a16711
work_keys_str_mv AT wangbr coprescriptionofchineseherbalmedicineandwesternmedicationamongfemalepatientswithbreastcancerintaiwananalysisofnationalinsuranceclaims
AT changyl coprescriptionofchineseherbalmedicineandwesternmedicationamongfemalepatientswithbreastcancerintaiwananalysisofnationalinsuranceclaims
AT chentj coprescriptionofchineseherbalmedicineandwesternmedicationamongfemalepatientswithbreastcancerintaiwananalysisofnationalinsuranceclaims
AT chiujh coprescriptionofchineseherbalmedicineandwesternmedicationamongfemalepatientswithbreastcancerintaiwananalysisofnationalinsuranceclaims
AT wujc coprescriptionofchineseherbalmedicineandwesternmedicationamongfemalepatientswithbreastcancerintaiwananalysisofnationalinsuranceclaims
AT wums coprescriptionofchineseherbalmedicineandwesternmedicationamongfemalepatientswithbreastcancerintaiwananalysisofnationalinsuranceclaims
AT choucl coprescriptionofchineseherbalmedicineandwesternmedicationamongfemalepatientswithbreastcancerintaiwananalysisofnationalinsuranceclaims
AT chouyc coprescriptionofchineseherbalmedicineandwesternmedicationamongfemalepatientswithbreastcancerintaiwananalysisofnationalinsuranceclaims